<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Despite the WHO recommendation that the 2010-2011 trivalent seasonal flu vaccine must contain A/California/7/2009/H1N1-like virus there is no consistent data regarding its immunogenicity and safety in a large autoimmune <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic disease</z:e> (ARD) population </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: 1668 ARD patients (<z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA), <z:e sem="disease" ids="C0038013" disease_type="Disease or Syndrome" abbrv="">ankylosing spondylitis</z:e> (AS), systemic <z:mp ids='MP_0000612'>sclerosis</z:mp>, psoriatic <z:hpo ids='HP_0001369'>arthritis</z:hpo> (PsA), <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease (BD), <z:e sem="disease" ids="C0026272" disease_type="Disease or Syndrome" abbrv="MCTD">mixed connective tissue disease</z:e>, <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS), <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e> (DM), primary <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sjögren's syndrome</z:e>, <z:e sem="disease" ids="C0039263" disease_type="Disease or Syndrome" abbrv="">Takayasu</z:e>'s <z:hpo ids='HP_0012089'>arteritis</z:hpo>, <z:e sem="disease" ids="C0085655" disease_type="Disease or Syndrome" abbrv="">polymyositis</z:e> and <z:hpo ids='HP_0002955'>Granulomatosis</z:hpo> with polyangiitis (Wegener's) (GPA)) and 234 healthy controls were vaccinated with a non-adjuvanted <z:e sem="disease" ids="C0021400" disease_type="Disease or Syndrome" abbrv="FLU">influenza</z:e> A/California/7/2009(H1N1) virus-like strain flu </plain></SENT>
<SENT sid="2" pm="."><plain>Subjects were evaluated before vaccination and 21 days post-vaccination </plain></SENT>
<SENT sid="3" pm="."><plain>The percentage of seroprotection, seroconversion and the factor increase in geometric mean titre (GMT) were calculated </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: /st&gt; After immunisation, seroprotection rates (68.5% vs 82.9% p&lt;0.0001), seroconversion rates (63.4% vs 76.9%, p&lt;0.001) and the factor increase in GMT (8.9 vs 13.2 p&lt;0.0001) were significantly lower in ARD than controls </plain></SENT>
<SENT sid="5" pm="."><plain>Analysis of specific diseases revealed that seroprotection significantly reduced in SLE (p&lt;0.0001), RA (p&lt;0.0001), PsA (p=0.0006), AS (p=0.04), BD (p=0.04) and DM (p=0.04) patients than controls </plain></SENT>
<SENT sid="6" pm="."><plain>The seroconversion rates in SLE (p&lt;0.0001), RA (p&lt;0.0001) and PsA (p=0.0006) patients and the increase in GMTs in SLE (p&lt;0.0001), RA (p&lt;0.0001) and PsA (p&lt;0.0001) patients were also reduced compared with controls </plain></SENT>
<SENT sid="7" pm="."><plain>Moderate and severe side effects were not reported </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The novel recognition of a diverse vaccine immunogenicity profile in distinct ARDs supports the notion that a booster dose may be recommended for diseases with suboptimal immune responses </plain></SENT>
<SENT sid="9" pm="."><plain>This large study also settles the issue of vaccine safety </plain></SENT>
<SENT sid="10" pm="."><plain>(ClinicalTrials.gov #NCT01151644) </plain></SENT>
</text></document>